Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
VTGN
#3997
Vistagen Therapeutics, Inc. Common Stock
0.607
3
USD
-3.73%
Sektor:
Gesundheitswesen
Basis:
USD
Gewinnwährung:
USD
Tagesspanne
Jahresspanne
Tagesänderung
-3.73%
Monatliche Änderung
+17.90%
6 month change
+17.90%
Jahresänderung
+17.90%
Vorheriger Schlusskurs
0.630
8
Open
0.607
3
Bid
0.607
3
Ask
0.610
3
Low
0.607
3
High
0.607
3
Volumen
6
Märkte
Aktien
Gesundheitswesen
VTGN
Open full chart
Financials
Overview
Finanzbericht
Statistics
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
28.86 M
29.16 M
30.68 M
39.5 M
39.62 M
—
Valuation ratios
Enterprise value
10.43 M
5.76 M
12.38 M
77.42 M
-21.15 M
74.42 M
Price to earnings ratio
-3.17
-1.5
-1.12
-1.86
-0.35
-4.82
Price to sales ratio
119.04
158.83
93.91
161.47
29.23
443.43
Price to cash flow ratio
-2.1
-1.83
-1.25
-2.17
-0.39
-5.63
Price to book ratio
0.2
1.1
0.21
0.41
0.09
1.81
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.15
0.16
0.22
0.24
0.29
0.91
Return on equity %
0.17
0.19
0.27
0.29
0.37
1.12
Return on invested capital %
1 097.64
1 064.54
1 079.78
1 372.79
1 533.47
5 050.58
Gross margin %
100
100
100
100
100
400
Operating margin %
7 560
76.29 K
6 477.05
7 772.48
6 450.83
96.99 K
EBITDA margin %
—
—
—
—
—
—
Net margin %
7 044.5
71.76 K
6 186.48
7 525.97
6 237.29
91.71 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
9.35
6.51
5.98
5.79
4.67
22.95
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0
0
0
0.01
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
0.01
0.01
0.01
—
Long term debt to total equity ratio
—
—
0.02
0.01
0.01
—
Per share metrics
Operating cash flow per share
0.33
0.33
0.59
0.39
0.42
1.72
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
2.88
2.61
1.98
2.16
1.46
8.21
Net current asset value per share
2.93
2.66
2.09
2.21
1.5
8.45
Tangible book value per share
2.64
2.28
1.78
1.86
1.21
7.12
Working capital per share
2.62
2.25
1.74
1.83
1.18
6.99
Book value per share
2.64
2.28
1.78
1.86
1.21
7.12
Nachrichten
Vistagen Therapeutics streicht 20 % der Stellen zur Kostensenkung
Vistagen Therapeutics reduces workforce by 20 percent to manage costs
VistaGen auf der TD Cowen Konferenz: Pherin-Plattform im Fokus
VistaGen at TD Cowen Conference: Pherine Platform in Focus
Vistagen Therapeutics: Verwaltungsratsmitglied Paul Edick tritt zurück
Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript
Earnings Call von VistaGen: KI-gestützte Analyse im Fokus der Q3-Ergebnisse 2026
Earnings call transcript: VistaGen Therapeutics Q3 2026 highlights AI-driven trial analysis
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates
Vistagen Therapeutics: Phase-3-Studie für Fasedienol verfehlt primären Endpunkt
Vistagen Therapeutics reports Phase 3 trial for fasedienol did not meet endpoint
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47%